The deal is expected to advance its cancer immunotherapy candidate VXM01, which has shown promising results in early studies for glioblastoma and pancreatic cancer. ・Under the agreement, BCME will get ...

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success ...

An estimated 8% of Americans live with autoimmune diseases that cause chronic inflammation and damage. Now, a breakthrough ...

After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – ...

The injection of immunotherapy directly into precancerous oral lesions may reduce risk for progression to cancer and help ...

Lund University. Immunotherapy harnesses the body’s own immune system to fight disease and has great potential, both in ...

The FDA granted regenerative medicine advanced therapy (RMAT) designation to Orca-Q, a second-generation investigational ...

Fecal microbiota transplantation is an emerging strategy for modulating the gut microbiome to influence immunotherapy ...

Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a team at Oregon Health & ...

Dr. David Greenberg outlines bladder cancer staging, BCG, immunotherapy, surgery, quality of life impacts and long-term ...

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.